The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Discover how poorer air quality due to smoke from Canadian wildfires in 2023 led to worsening asthma symptoms in children in ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Heat therapy can help mood, pain and immunity, but experts warn against dehydration, long sessions and alcohol ...

It’s awful to think our air is full of contaminants. We inhale about 35 pounds of air per day. But did you know the air inside your home could be ...

There’s a big opportunity for MAHA to include real-world experts in future studies and analyses: mental-health professionals, ...

Daily air purifier use helps support cleaner air, which can lead to allergy relief, better heart and lung health, and other benefits to your health.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

Collaborations between housing and health are crucial to protecting residents from hazards associated with poor air quality, ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...